RBC Europe’s Xenetic Biosciences XBIO Stock Holding History

RBC Europe’s Portfolio XBIO Stock Details XBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11	Closed	-$217	–	1169
2021 Q3	$217	Hold	11	–	–	﹤0.01%	1210
2021 Q2	$216	Hold	11	–	–	﹤0.01%	1205
2021 Q1	$231	Hold	11	–	–	﹤0.01%	1158
2020 Q4	$216	Hold	11	–	–	﹤0.01%	1131
2020 Q3	$96	Hold	11	–	–	﹤0.01%	1080
2020 Q2	$108	Hold	11	–	–	﹤0.01%	1043
2020 Q1	$78	Hold	11	–	–	﹤0.01%	1024
2019 Q4	$153	Hold	11	–	–	﹤0.01%	1026
2019 Q3	$127	Hold	11	–	–	﹤0.01%	1030
2019 Q2	$1.18K	Hold	11	–	–	﹤0.01%	1005
2019 Q1	$2.47K	Hold	11	–	–	﹤0.01%	985
2018 Q4	$2.08K	Hold	11	–	–	﹤0.01%	998
2018 Q3	$3.6K	Hold	11	–	–	﹤0.01%	994
2018 Q2	$5.19K	Hold	11	–	–	﹤0.01%	967
2018 Q1	$2.73K	Sell	11 -8	-42%	-$2K	﹤0.01%	1029
2017 Q4	$4.3K	Hold	19	–	–	﹤0.01%	980
2017 Q3	$4.52K	Buy	+19	New	+$6.14K	﹤0.01%	965

Other funds holding XBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

RBC Europe's XBIO Position: Q4 2021 in Review

RBC Europe sold out of Xenetic Biosciences (XBIO) in Q4 2021, closing a stake of 11 shares — an estimated $217 sold.

RBC Europe first reported a position in XBIO in Q3 2017 and held it in 17 quarters. The position peaked at $5.19K in Q2 2018. 22 funds tracked by Wall St. Rank hold XBIO as of Q4 2021.

RBC Europe reported no remaining Xenetic Biosciences position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 11 Xenetic Biosciences shares in Q4 2021, an estimated $217.
RBC Europe first reported a position in Xenetic Biosciences in Q3 2017 and held it in 17 quarters.
RBC Europe's Xenetic Biosciences position peaked at $5.19K in Q2 2018.
22 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.